Sandoz Group AG (SDZ.SW) stock analysis

In our weekly check, Sandoz Group AG is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 24 pass, warnings: 1, red flags: 0.

About Sandoz Group AG

Sandoz Group AG is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Switzerland, listed on SIX as SDZ.SW.

What our checks show for SDZ.SW

Warning signs

• The net margin is only 8.6%: little room if costs rise.

Strengths

• The gross margin is 47.4% and has risen by 4 points: pricing power is holding.
• Operating cash flow is 1.66x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 35.2% a year over the next years.
• Analysts expect the net margin to improve by 11.2 points from today's 8.6%.
• The dividend takes 33% of profit: there is a cushion.
• A large company: market value $42.35 billion.

Similar companies

ZTS · GALD.SW · HLN · TEVA · VTRS · MRK.DE

Questions

What grade does Sandoz Group AG (SDZ.SW) have?

In our weekly check, Sandoz Group AG is graded A (A to F). Of 25 checks on debt, profit, cash flow and trend: 24 pass, warnings: 1, red flags: 0. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of SDZ.SW stock?

This week's biggest flags for Sandoz Group AG: Thin margins. In total 1 of 25 checks show a warning or a red flag.

What does Sandoz Group AG do?

Sandoz Group AG is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Switzerland, listed on SIX as SDZ.SW.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis